Skip to main content
Erschienen in: Herz 1/2016

01.02.2016 | Main Topic

Interventional approaches to mitral regurgitation

What’s in the pipeline?

verfasst von: V. Mauri, S. Baldus, Prof. Dr. med. V. Rudolph

Erschienen in: Herz | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Mitral regurgitation (MR) is the most prevalent valvular heart disease in the Western world. Surgical repair is the gold standard for the treatment of degenerative MR in low-risk patients. Given the rising number of patients with functional MR and higher operative risk due to relevant comorbidities and increasing age, interventional approaches to repair or replace diseased mitral valves are on the rise. However, the complex anatomy and physiology of the mitral valve and its adjacent valve apparatus bear major challenges. To date, only the MitraClip device has been used in a large number of patients; however, several other devices and systems specifically targeted at different underlying pathologies of MR are currently under development. In addition to valve repair, the first steps toward mitral valve replacement have been taken. The present article reviews the current state of the art of interventional approaches to mitral valve disease and its future perspectives.
Literatur
4.
5.
Zurück zum Zitat Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM (2005) Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 45(3):381–387. doi:10.1016/j.jacc.2004.09.073 CrossRefPubMed Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM (2005) Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 45(3):381–387. doi:10.​1016/​j.​jacc.​2004.​09.​073 CrossRefPubMed
6.
Zurück zum Zitat Diodato MD, Moon MR, Pasque MK, Barner HB, Moazami N, Lawton JS, Bailey MS, Guthrie TJ, Meyers BF, Damiano RJ Jr (2004) Repair of ischemic mitral regurgitation does not increase mortality or improve long-term survival in patients undergoing coronary artery revascularization: a propensity analysis. Ann Thorac Surg 78(3):794–799. doi:10.1016/j.athoracsur.2004.03.022 CrossRefPubMed Diodato MD, Moon MR, Pasque MK, Barner HB, Moazami N, Lawton JS, Bailey MS, Guthrie TJ, Meyers BF, Damiano RJ Jr (2004) Repair of ischemic mitral regurgitation does not increase mortality or improve long-term survival in patients undergoing coronary artery revascularization: a propensity analysis. Ann Thorac Surg 78(3):794–799. doi:10.​1016/​j.​athoracsur.​2004.​03.​022 CrossRefPubMed
7.
Zurück zum Zitat Mirabel M, Iung B, Baron G, Messika-Zeitoun D, Detaint D, Vanoverschelde JL, Butchart EG, Ravaud P, Vahanian A (2007) What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J 28(11):1358–1365. doi:10.1093/eurheartj/ehm001 CrossRefPubMed Mirabel M, Iung B, Baron G, Messika-Zeitoun D, Detaint D, Vanoverschelde JL, Butchart EG, Ravaud P, Vahanian A (2007) What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J 28(11):1358–1365. doi:10.​1093/​eurheartj/​ehm001 CrossRefPubMed
8.
Zurück zum Zitat Thyregod HG, Steinbruchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, Chang Y, Franzen OW, Engstrom T, Clemmensen P, Hansen PB, Andersen LW, Olsen PS, Sondergaard L (2015) Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol 65(20):2184–2194. doi:10.1016/j.jacc.2015.03.014 CrossRefPubMed Thyregod HG, Steinbruchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, Chang Y, Franzen OW, Engstrom T, Clemmensen P, Hansen PB, Andersen LW, Olsen PS, Sondergaard L (2015) Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol 65(20):2184–2194. doi:10.​1016/​j.​jacc.​2015.​03.​014 CrossRefPubMed
10.
Zurück zum Zitat Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, Fajadet J, Shah AM, Feldman T, Kaye DM, Goldberg SL, Levy WC, Solomon SD, Reuter DG (2012) Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. Eur J Heart Fail 14(8):931–938. doi:10.1093/eurjhf/hfs076 PubMedCentralCrossRefPubMed Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, Fajadet J, Shah AM, Feldman T, Kaye DM, Goldberg SL, Levy WC, Solomon SD, Reuter DG (2012) Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. Eur J Heart Fail 14(8):931–938. doi:10.​1093/​eurjhf/​hfs076 PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Schofer J, Siminiak T, Haude M, Herrman JP, Vainer J, Wu JC, Levy WC, Mauri L, Feldman T, Kwong RY, Kaye DM, Duffy SJ, Tubler T, Degen H, Brandt MC, Van Bibber R, Goldberg S, Reuter DG, Hoppe UC (2009) Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study. Circulation 120(4):326–333. doi:10.1161/CIRCULATIONAHA.109.849885 PubMedCentralCrossRefPubMed Schofer J, Siminiak T, Haude M, Herrman JP, Vainer J, Wu JC, Levy WC, Mauri L, Feldman T, Kwong RY, Kaye DM, Duffy SJ, Tubler T, Degen H, Brandt MC, Van Bibber R, Goldberg S, Reuter DG, Hoppe UC (2009) Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study. Circulation 120(4):326–333. doi:10.​1161/​CIRCULATIONAHA.​109.​849885 PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Maisano F, La Canna G, Latib A, Denti P, Taramasso M, Kuck KH, Colombo A, Alfieri O, Guidotti A, Messika-Zeitoun D, Vahanian A (2014) First-in-man transseptal implantation of a “surgical-like” mitral valve annuloplasty device for functional mitral regurgitation. JACC Cardiovasc Interv 7(11):1326–1328. doi:10.1016/j.jcin.2014.08.003 CrossRefPubMed Maisano F, La Canna G, Latib A, Denti P, Taramasso M, Kuck KH, Colombo A, Alfieri O, Guidotti A, Messika-Zeitoun D, Vahanian A (2014) First-in-man transseptal implantation of a “surgical-like” mitral valve annuloplasty device for functional mitral regurgitation. JACC Cardiovasc Interv 7(11):1326–1328. doi:10.​1016/​j.​jcin.​2014.​08.​003 CrossRefPubMed
14.
Zurück zum Zitat Siminiak T, Dankowski R, Baszko A, Lee C, Firek L, Kalmucki P, Szyszka A, Groothuis A (2013) Percutaneous direct mitral annuloplasty using the Mitralign Bident system: description of the method and a case report. Kardiol Pol 71(12):1287–1292. doi:10.5603/KP.2013.0325 CrossRefPubMed Siminiak T, Dankowski R, Baszko A, Lee C, Firek L, Kalmucki P, Szyszka A, Groothuis A (2013) Percutaneous direct mitral annuloplasty using the Mitralign Bident system: description of the method and a case report. Kardiol Pol 71(12):1287–1292. doi:10.​5603/​KP.​2013.​0325 CrossRefPubMed
15.
Zurück zum Zitat Rogers JH, Thomas M, Morice MC, Narbute I, Zabunova M, Hovasse T, Poupineau M, Rudzitis A, Kamzola G, Zvaigzne L, Greene S, Erglis A (2015) Treatment of heart failure with associated functional mitral regurgitation using the ARTO System: initial results of the First-in-Human MAVERIC Trial (Mitral Valve Repair Clinical Trial). JACC Cardiovasc Interv 8(8):1095–1104. doi:10.1016/j.jcin.2015.04.012 CrossRefPubMed Rogers JH, Thomas M, Morice MC, Narbute I, Zabunova M, Hovasse T, Poupineau M, Rudzitis A, Kamzola G, Zvaigzne L, Greene S, Erglis A (2015) Treatment of heart failure with associated functional mitral regurgitation using the ARTO System: initial results of the First-in-Human MAVERIC Trial (Mitral Valve Repair Clinical Trial). JACC Cardiovasc Interv 8(8):1095–1104. doi:10.​1016/​j.​jcin.​2015.​04.​012 CrossRefPubMed
16.
Zurück zum Zitat Maisano F, Cioni M, Seeburger J, Falk V, Mohr FW, Mack MJ, Alfieri O, Vanermen H (2011) Beating-heart implantation of adjustable length mitral valve chordae: acute and chronic experience in an animal model. Eur J Cardiothorac Surg 40(4):840–847. doi:10.1016/j.ejcts.2011.01.021 PubMed Maisano F, Cioni M, Seeburger J, Falk V, Mohr FW, Mack MJ, Alfieri O, Vanermen H (2011) Beating-heart implantation of adjustable length mitral valve chordae: acute and chronic experience in an animal model. Eur J Cardiothorac Surg 40(4):840–847. doi:10.​1016/​j.​ejcts.​2011.​01.​021 PubMed
17.
Zurück zum Zitat Seeburger J, Rinaldi M, Nielsen SL, Salizzoni S, Lange R, Schoenburg M, Alfieri O, Borger MA, Mohr FW, Aidietis A (2014) Off-pump transapical implantation of artificial neo-chordae to correct mitral regurgitation: the TACT Trial (Transapical Artificial Chordae Tendinae) proof of concept. J Am Coll Cardiol 63(9):914–919. doi:10.1016/j.jacc.2013.07.090 CrossRefPubMed Seeburger J, Rinaldi M, Nielsen SL, Salizzoni S, Lange R, Schoenburg M, Alfieri O, Borger MA, Mohr FW, Aidietis A (2014) Off-pump transapical implantation of artificial neo-chordae to correct mitral regurgitation: the TACT Trial (Transapical Artificial Chordae Tendinae) proof of concept. J Am Coll Cardiol 63(9):914–919. doi:10.​1016/​j.​jacc.​2013.​07.​090 CrossRefPubMed
18.
Zurück zum Zitat Rucinskas K, Janusauskas V, Zakarkaite D, Aidietiene S, Samalavicius R, Speziali G, Aidietis A (2014) Off-pump transapical implantation of artificial chordae to correct mitral regurgitation: early results of a single-center experience. J Thorac Cardiovasc Surg 147(1):95–99. doi:10.1016/j.jtcvs.2013.08.012 CrossRefPubMed Rucinskas K, Janusauskas V, Zakarkaite D, Aidietiene S, Samalavicius R, Speziali G, Aidietis A (2014) Off-pump transapical implantation of artificial chordae to correct mitral regurgitation: early results of a single-center experience. J Thorac Cardiovasc Surg 147(1):95–99. doi:10.​1016/​j.​jtcvs.​2013.​08.​012 CrossRefPubMed
21.
23.
Zurück zum Zitat Guerrero M, Greenbaum A, O’Neill W (2014) First in human percutaneous implantation of a balloon expandable transcatheter heart valve in a severely stenosed native mitral valve. Catheter Cardiovasc Interv 83(7):E287–E291. doi:10.1002/ccd.25441 CrossRefPubMed Guerrero M, Greenbaum A, O’Neill W (2014) First in human percutaneous implantation of a balloon expandable transcatheter heart valve in a severely stenosed native mitral valve. Catheter Cardiovasc Interv 83(7):E287–E291. doi:10.​1002/​ccd.​25441 CrossRefPubMed
25.
Zurück zum Zitat Bapat V, Buellesfeld L, Peterson MD, Hancock J, Reineke D, Buller C, Carrel T, Praz F, Rajani R, Fam N, Kim H, Redwood S, Young C, Munns C, Windecker S, Thomas M (2014) Transcatheter mitral valve implantation (TMVI) using the Edwards FORTIS device. EuroIntervention 10(Suppl U):U120–U128. doi:10.4244/EIJV10SUA18 CrossRefPubMed Bapat V, Buellesfeld L, Peterson MD, Hancock J, Reineke D, Buller C, Carrel T, Praz F, Rajani R, Fam N, Kim H, Redwood S, Young C, Munns C, Windecker S, Thomas M (2014) Transcatheter mitral valve implantation (TMVI) using the Edwards FORTIS device. EuroIntervention 10(Suppl U):U120–U128. doi:10.​4244/​EIJV10SUA18 CrossRefPubMed
26.
Zurück zum Zitat Cheung A, Stub D, Moss R, Boone RH, Leipsic J, Verheye S, Banai S, Webb J (2014) Transcatheter mitral valve implantation with Tiara bioprosthesis. EuroIntervention 10(Suppl U):U115–119. doi:10.4244/EIJV10SUA17 CrossRefPubMed Cheung A, Stub D, Moss R, Boone RH, Leipsic J, Verheye S, Banai S, Webb J (2014) Transcatheter mitral valve implantation with Tiara bioprosthesis. EuroIntervention 10(Suppl U):U115–119. doi:10.​4244/​EIJV10SUA17 CrossRefPubMed
27.
Zurück zum Zitat Moat N, Duncan A, Lindsay A, Quarto C, Blanke P, Leipsic J, Grayburn P, Davies S (2015) Transcatheter mitral valve replacement for the treatment of mitral regurgitation: in-hospital outcomes of an apically tethered device. J Am Coll Cardiol 65(21):2352–2353. doi:10.1016/j.jacc.2015.01.066 CrossRefPubMed Moat N, Duncan A, Lindsay A, Quarto C, Blanke P, Leipsic J, Grayburn P, Davies S (2015) Transcatheter mitral valve replacement for the treatment of mitral regurgitation: in-hospital outcomes of an apically tethered device. J Am Coll Cardiol 65(21):2352–2353. doi:10.​1016/​j.​jacc.​2015.​01.​066 CrossRefPubMed
28.
Zurück zum Zitat Ussia GP, Quadri A, Cammalleri V, De Vico P, Muscoli S, Marchei M, Ruvolo G, Sondergaard L, Romeo F (2015) Percutaneous transfemoral-transseptal implantation of a second-generation CardiAQ mitral valve bioprosthesis: first procedure description and 30-day follow-up. EuroIntervention 11(5). doi:10.4244/EIJY15M09_01 Ussia GP, Quadri A, Cammalleri V, De Vico P, Muscoli S, Marchei M, Ruvolo G, Sondergaard L, Romeo F (2015) Percutaneous transfemoral-transseptal implantation of a second-generation CardiAQ mitral valve bioprosthesis: first procedure description and 30-day follow-up. EuroIntervention 11(5). doi:10.​4244/​EIJY15M09_​01
Metadaten
Titel
Interventional approaches to mitral regurgitation
What’s in the pipeline?
verfasst von
V. Mauri
S. Baldus
Prof. Dr. med. V. Rudolph
Publikationsdatum
01.02.2016
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe 1/2016
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-015-4384-2

Weitere Artikel der Ausgabe 1/2016

Herz 1/2016 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.